Loading...
XSTORAY B
Market cap645mUSD
Dec 23, Last price  
208.00SEK
1D
1.96%
1Q
35.95%
Jan 2017
12.74%
Name

RaySearch Laboratories AB (publ)

Chart & Performance

D1W1MN
XSTO:RAY B chart
P/E
87.42
P/S
6.98
EPS
2.38
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
10.26%
Revenues
1.02b
+21.16%
39,479,00069,855,00068,976,00064,705,00062,690,00083,687,000117,728,000126,103,000182,087,000204,470,000285,217,000397,600,000531,468,000585,086,000627,219,000741,584,000651,612,000641,673,000843,648,0001,022,159,000
Net income
82m
+243.06%
12,903,00029,142,00036,219,00019,779,00018,223,00030,146,00028,895,00017,007,00019,863,000-20,841,00059,832,00070,209,000151,408,000117,627,00078,523,00050,411,000-9,080,000-47,315,00023,778,00081,572,000
CFO
456m
+27.79%
12,872,00041,393,00030,093,00037,862,00026,045,00049,207,00062,785,00033,852,00087,451,00031,282,00050,273,000111,426,000120,848,000147,481,000178,472,000320,145,000331,508,000238,162,000356,777,000455,931,000
Dividend
May 23, 20241.3 SEK/sh
Earnings
Feb 21, 2025

Profile

RaySearch Laboratories AB (publ), a medical technology company, develops software solutions for cancer treatment worldwide. It develops and markets RayStation, a treatment planning system for treatment activities, such as automated planning, adaptive therapy, multi-criteria optimization, fast and accurate dose computations, OAR dose reduction, robustness, machine learning, VMAT, IMRT, 3D-CRT, virtual simulation, electron beam therapy, tomotherapy, stereotactic, proton therapy, carbon ion therapy, and boron neutron capture therapy. The company also develops RayPlan, a treatment planning system for supporting a range of treatment planning activities for 3D-CRT, IMRT, VMAT, tomotherapy, and electron beam radiation therapy; and RayCare, an oncology information system to support cancer treatment activities. In addition, it offers RayCommand, a treatment control system that is compatible with various hardware models and supports advanced functionalities of treatment machines and software systems; and RayIntelligence, a cloud-based oncology analytics system that turns patient data into insights. Further, the company provides training courses related to its products. RaySearch Laboratories AB (publ) is headquartered in Stockholm, Sweden.
URL
https://www.raysearchlabs.com/
IPO date
May 29, 1990
Employees
375
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
1,022,159
21.16%
843,648
31.48%
641,673
-1.53%
Cost of revenue
902,323
814,903
706,068
Unusual Expense (Income)
NOPBT
119,836
28,745
(64,395)
NOPBT Margin
11.72%
3.41%
Operating Taxes
28,516
8,597
(11,358)
Tax Rate
23.80%
29.91%
NOPAT
91,320
20,148
(53,037)
Net income
81,572
243.06%
23,778
-150.25%
(47,315)
421.09%
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
97,381
58,307
70,381
Long-term debt
961,335
1,052,464
1,031,147
Deferred revenue
Other long-term liabilities
878
743
879
Net debt
691,415
895,806
991,137
Cash flow
Cash from operating activities
455,931
356,777
238,162
CAPEX
(24,295)
(231,501)
(255,222)
Cash from investing activities
(209,330)
(231,501)
(237,631)
Cash from financing activities
(56,350)
(78,492)
(72,234)
FCF
149,974
111,830
(534,100)
Balance
Cash
343,681
160,268
102,535
Long term investments
23,620
54,697
7,856
Excess cash
316,193
172,783
78,307
Stockholders' equity
733,257
657,551
654,739
Invested Capital
949,275
1,035,522
1,129,535
ROIC
9.20%
1.86%
ROCE
8.72%
2.19%
EV
Common stock shares outstanding
34,283
34,283
34,283
Price
90.30
32.79%
68.00
20.35%
56.50
-31.68%
Market cap
3,095,734
32.79%
2,331,229
20.35%
1,936,977
-31.68%
EV
3,787,149
3,229,405
2,935,550
EBITDA
405,990
325,745
185,605
EV/EBITDA
9.33
9.91
15.82
Interest
9,687
11,478
6,036
Interest/NOPBT
8.08%
39.93%